Equities

ChengDu Sheng Nuo Biotec Co Ltd

688117:SHH

ChengDu Sheng Nuo Biotec Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)28.00
  • Today's Change-1.92 / -6.42%
  • Shares traded3.17m
  • 1 Year change-1.55%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments268372410
Total Receivables, Net136149131
Total Inventory194135101
Prepaid expenses9.949.778.14
Other current assets, total1.28--1.27
Total current assets609666652
Property, plant & equipment, net484285238
Goodwill, net------
Intangibles, net534846
Long term investments94569.90
Note receivable - long term------
Other long term assets------
Total assets1,3161,108957
LIABILITIES
Accounts payable56328.15
Accrued expenses151512
Notes payable/short-term debt435030
Current portion long-term debt/capital leases352.750.68
Other current liabilities, total94125111
Total current liabilities241225162
Total long term debt190492.17
Total debt26710233
Deferred income tax--1.07--
Minority interest0.17----
Other liabilities, total4.565.726.85
Total liabilities436281171
SHAREHOLDERS EQUITY
Common stock1128080
Additional paid-in capital379408407
Retained earnings (accumulated deficit)389338298
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity880827785
Total liabilities & shareholders' equity1,3161,108957
Total common shares outstanding112112112
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.